Kutatási jelek – Signal Engine

• LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma — Diffuse large B-cell lymphoma
• Treatment Decisions in Multiple Myeloma — Multiple myeloma
• Kite Pharma announces positive results for patients with relapsed or refractory acute lymphoblastic leukemia after receiving anti‑CD19 CAR‑T cells — Acute lymphoblastic leukemia
• FAPI Radionuclide Theranostics Show Promise in Sarcoma Diagnosis and Treatment — Colorectal cancer
• Breast Cancer — Breast cancer
• Goal-Based Nutrition Support May Not Limit Muscle Loss in Esophageal Cancer — Esophageal cancer
• Role of radiotherapy in refractory/relapsed classical Hodgkin lymphoma in the era of targeted therapies and immunotherapy — Hodgkin lymphoma
• Gilead Announces Top Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis — Myelofibrosis
• A trial looking at CY-101 for advanced adrenal cortical cancer (CLARITY) — Gastrointestinal stromal tumor
• Patient questionnaires may add a new layer to chronic lymphocytic leukemia prognosis — Chronic lymphocytic leukemia
• Becotatug Vedotin Plus Pucotenlimab and... | Clinical Trial — Colorectal cancer
• People with lung cancer have more microplastics in their lungs — Lung cancer
• Stomach Cancer — Gastric cancer
• Biotech Catalyst Calendar – Trial Readout Dates by Month – SPZCO — NSCLC
• Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer — Thyroid cancer
• Biomarker-Independent ADC Rina-S Advances to Phase 3 in Endometrial Cancer — Endometrial cancer
• Mount Sinai Study Finds Chemotherapy-Free Treatment Shows Promise for Some Patients With Metastatic Breast Cancer — Breast cancer
• Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology — NSCLC
• New fibroblast state reveals how lung tumors may suppress immune defenses — NSCLC
• Spatial profiling of the spleen in mouse and human myelofibrosis reveals complement‑driven immune‑stromal interactions as a therapeutic target. — Myelofibrosis